Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA7 | P43166 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL151213 | 0.89 | CA1 (0.61) | SMN1; SMN2CA1CA2CA12CA7 | |
| SCHEMBL27753904 | 0.89 | CA1 (0.61) | SMN1; SMN2CA1CA2CA12CA7 | |
| SCHEMBL25434306 | 0.89 | CA1 (0.61) | SMN1; SMN2CA1CA2CA12CA7 | |
| Bromide SCHEMBL28158222 | 0.87 | SMN1; SMN2 (0.58) | SMN1; SMN2CA1CA2CA12CA7 | |
| Ammonia Solution, Strong SCHEMBL4268652 | 0.87 | SMN1; SMN2 (0.58) | SMN1; SMN2CA1CA2CA12CA7 | |
| Hydrochloric Acid SCHEMBL31658961 | 0.87 | SMN1; SMN2 (0.58) | SMN1; SMN2CA1CA2CA12CA7 | |
| SCHEMBL27731704 | 0.87 | SMN1; SMN2 (0.58) | SMN1; SMN2CA1CA2CA12CA7 | |
| SCHEMBL26816106 | 0.87 | SMN1; SMN2 (0.50) | SMN1; SMN2CA1CA2CA12CA7 | |
| Bromide SCHEMBL1307432 | 0.84 | SMN1; SMN2 (0.56) | SMN1; SMN2CA1CA2CA12CA7 | |
| Methylamine SCHEMBL27494863 | 0.84 | SMN1; SMN2 (0.56) | SMN1; SMN2CA1CA2CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114085184-B | Biphenyl derivative containing cyclopropane structure and preparation method and application thereof | 中山大学 | 2023-08-29 | — | — | CN | disclosed |
| CN-114085184-A | Biphenyl derivative containing cyclopropane structure and preparation method and application thereof | 中山大学 | 2022-02-25 | — | — | CN | disclosed |
| EP-2817313-B1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-09-07 | — | — | EP | disclosed |
| EP-2609100-B1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-06-24 | — | — | EP | disclosed |
| US-9006440-B2 | Furopyridine derivatives | MERCK PATENT GMBH (DE) | 2015-04-14 | — | — | US | disclosed |
| US-20150038527-A1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-02-05 | — | — | US | disclosed |
| EP-2817313-A1 | FUROPYRIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2014-12-31 | — | — | EP | disclosed |
| US-20130225569-A1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
| WO-2013124025-A1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-29 | — | — | WO | disclosed |
| EP-2620429-A1 | Hydroxylamine compounds and methods of their use | Colby Pharmaceutical Company (US) | 2013-07-31 | — | — | EP | disclosed |
| US-6900213-B2 | Bisaryl derivatives having FSH modulatory activity | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1351941-B1 | BISARYL DERIVATIVES HAVING FSH RECEPTOR MODULATORY ACTIVITY | PHARMACOPEIA INC (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20040152703-A1 | Bisaryl derivatives having FSH modulatory activity | PHARMACOPEIA, LLC | 2004-08-05 | — | — | US | disclosed |
| US-20040143023-A1 | Materials and methods for synthesizing stilbenes | HADFIELD JOHN ANTHONY (GB) | 2004-07-22 | — | — | US | disclosed |
| WO-2004041285-A1 | ANTIINFLAMMATION AGENTS | AMGEN INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040097485-A1 | Antiinflammation agents | TULARIK INC. | 2004-05-20 | — | — | US | disclosed |
| EP-1351941-A1 | BISARYL DERIVATIVES HAVING FSH RECEPTOR MODULATORY ACTIVITY | PHARMACOPEIA, INC. (US) | 2003-10-15 | — | — | EP | disclosed |
| EP-1351911-A2 | MATERIALS AND METHODS FOR SYNTHESIZING STILBENES | Cancer Research Ventures Limited (GB) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002070493-A1 | BISARYL DERIVATIVES HAVING FSH RECEPTOR MODULATORY ACTIVITY | PHARMACOPEIA, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| WO-2002049994-A2 | MATERIALS AND METHODS FOR SYNTHESIZING STILBENES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152703-A1 | Bisaryl derivatives having FSH modulatory activity | FSHR, GNRHR, LHCGR | SMN1; SMN2 4552/4885CA1 4540/4885CA2 3933/4885 |
| US-20150038527-A1 | FUROPYRIDINE DERIVATIVES | SYK, LYN, BTK | SMN1; SMN2 4397/4885CA1 3747/4885CA2 2738/4885 |
| US-20040143023-A1 | Materials and methods for synthesizing stilbenes | DPP4, COASY, ACSL4 | SMN1; SMN2 3665/4885CA1 834/4885CA2 741/4885 |
| US-20130225569-A1 | FUROPYRIDINE DERIVATIVES | SYK, FCGRT, SSB | SMN1; SMN2 4592/4885CA1 3786/4885CA2 2471/4885 |
| US-20040097485-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | SMN1; SMN2 4729/4885CA1 4473/4885CA2 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.